Legal Representation
Attorney
Nancy Sabarra
USPTO Deadlines
Application History
28 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 29, 2025 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Jul 29, 2025 | GNSL | F | LETTER OF SUSPENSION E-MAILED | Loading... |
| Jul 29, 2025 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jul 29, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 29, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 24, 2025 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| May 2, 2025 | GNS2 | O | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | Loading... |
| May 2, 2025 | GNSI | S | INQUIRY TO SUSPENSION E-MAILED | Loading... |
| May 2, 2025 | CNSI | R | SUSPENSION INQUIRY WRITTEN | Loading... |
| May 2, 2025 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | Loading... |
| Nov 1, 2024 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Nov 1, 2024 | GNSL | F | LETTER OF SUSPENSION E-MAILED | Loading... |
| Nov 1, 2024 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Sep 23, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 23, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 23, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 18, 2024 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Jun 18, 2024 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Mar 21, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 21, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 21, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 20, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 23, 2024 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Jan 23, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Sep 1, 2023 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Sep 13, 2023 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Sep 12, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 17, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations and substances for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein or nucleic acids or viral vectors for therapy; medicine for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; medical preparations for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for medical purposes for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; biological preparations comprising exosome for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations comprising a therapeutic target protein-loaded, nucleic acid-loaded or virus-loaded exosome for the treatment of genetic diseases, respiratory diseases, or cancer; biological preparations comprising exosome sold as a component of pharmaceuticals for the treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological reagents for medical use; mixed biological preparations for medical purposes for the prevention and treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle (EV)-based nucleic acid therapeutics for the prevention and treatment of infections or cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; all of the foregoing excluding such goods or services in the fields of constipation, gut health, weight loss, appetite suppressants, dietetic preparations, and nutrition
Class 042
Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; research and analysis services in the field of pharmaceuticals; biological research; clinical research in the field of clinical research in the field of transformational therapeutics; providing medical research and scientific research information in the field of filtration of exosomes from cultured cells or blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; medical laboratory diagnostics research services; information, advisory and consultancy services relating to the aforesaid; none of the foregoing in the fields of information technology and information technology systems; all of the foregoing excluding such goods or services in the fields of constipation, gut health, weight loss, appetite suppressants, dietetic preparations, and nutrition
Class 044
Pharmaceutical consultancy; medical diagnostic services; medical analysis for the diagnosis and treatment of persons and medical examinations; medical treatment services; medical screening; medical monitoring, testing, and inspection services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases; medical monitoring, testing, and inspection services relating to the diagnosis and treatment of cancer, diabetes, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; information, advisory and consultancy services relating to the aforesaid
Additional Information
Design Mark
The mark consists of the word "EVOX" with the letters "E", "V" and "X" in the color gray and with the letter "O" formed by circles in the color green.
Color Claim
The color(s) gray and green is/are claimed as a feature of the mark.
Classification
International Classes
005
042
044